Sequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusion

Sequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusion

Purpose To evaluate the efficacy and safety of sequential therapy with ranibizumab followed by dexamethasone intravitreal implant compared with dexamethasone monotherapy for macular oedema (MO) secondary to retinal vein occlusion (RVO). Methods In this retrospective interventional study, the medical...

Descripció completa

Dades bibliogràfiques
Autors principals:	Iu, L, Zhao, P, Yeung, I, Fung, N, Lee, J, Wong, R, Chong, V, Wong, I
Format:	Journal article
Idioma:	English
Publicat:	BMJ Publishing Group 2014

Ítems similars

Comparison of intravitreal ranibizumab monotherapy vs. ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion
per: Xuemei Liang, et al.
Publicat: (2022-09-01)

Efficacy of Intravitreal Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion and Resistant to Intravitreal Ranibizumab Injection
per: Ayşe Ergin, et al.
Publicat: (2022-12-01)

A Real-Life Study: Intravitreal Aflibercept, Ranibizumab and Dexamethasone for Macular Edema Secondary to Branch Retinal Vein Occlusion
per: Alper Halil Bayat, et al.
Publicat: (2019-12-01)

Repeated Treatment for Macular Edema in Vein Occlusion by Intravitreal Implant of Dexamethasone
per: Frederic Matonti, et al.
Publicat: (2012-10-01)

Effects of Dexamethasone Intravitreal Implant on Multifocal Electroretinography in Diabetic Macular Oedema
per: Tranos P, et al.
Publicat: (2024-11-01)

Budget impact analysis of dexamethasone intravitreal implant for the treatment of diabetic macular oedema
per: Fernando de Andrés-Nogales, et al.
Publicat: (2018-11-01)

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
per: Antoine Herbaut, et al.
Publicat: (2017-01-01)

Comparison of Intravitreal Dexamethasone Implant and Ranibizumab in Vitrectomized Eyes with Diabetic Macular Edema
per: Jia-Kang Wang, et al.
Publicat: (2021-01-01)

Macular Electrophysiology After Intravitreal Dexamethasone Implant in Patients with Branch Retinal Vein Occlusion
per: Muhammed Nurullah Bulut, et al.
Publicat: (2020-03-01)

Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex)
per: Mohamed Loutfi, et al.
Publicat: (2014-01-01)

Comparison of Ranibizumab alone versus Ranibizumab with Targeted Retinal Laser for Branch Retinal Vein Occlusion with Macular Oedema.
per: Mohamed Abdelmoneem, et al.
Publicat: (2022-10-01)

Comparison of changes in number of hyperreflective dots after intravitreal ranibizumab or dexamethasone implant in patients with branch retinal vein occlusion
per: Aylin Karalezli, et al.
Publicat: (2023-05-01)

Intravitreal Injection of Conbercept Combined with Dexamethasone for Macular Edema Following Central Retinal Vein Occlusion
per: Wu P, et al.
Publicat: (2024-06-01)

Long-term Results of Ranibizumab, Dexamethasone Implant, and Triamcinolone in Macular Edema due to Branch Retinal Vein Occlusion
per: Nevin Hande Dikel, et al.
Publicat: (2019-12-01)

Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema
per: Santosh K Mahapatra, et al.
Publicat: (2024-01-01)

Intravitreal Injection of Dexamethasone Implant and Ranibizumab in Cystoid Macular Edema in the Course of Irvine-Gass Syndrome
per: Vito Fenicia, et al.
Publicat: (2014-08-01)

The Application of Structural Retinal Biomarkers to Evaluate the Effect of Intravitreal Ranibizumab and Dexamethasone Intravitreal Implant on Treatment of Diabetic Macular Edema
per: Ida Ceravolo, et al.
Publicat: (2020-06-01)

Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema.
per: Ahmed Abdel-Hay, et al.
Publicat: (2018-01-01)

INTRAVITREAL IMPLANT OF DEXAMETHASONE IN THE TREATMENT OF RETINAL VEIN OCCLUSION: EFFICACY AND SAFETY
per: A. E. Yavorskiy, et al.
Publicat: (2015-10-01)

Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion.
per: Chen, S, et al.
Publicat: (2004)

Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
per: Alex Yuan, et al.
Publicat: (2014-02-01)

Combined dexamethasone intravitreal implant (Ozurdex) and macular grid laser versus combined intravitreal bevacizumab and macular grid laser in branch retinal vein occlusion with macular edema
per: Abdelrahman G Salman
Publicat: (2015-01-01)

Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study
per: Paul Mitchell, et al.
Publicat: (2023-06-01)

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
per: Laine I, et al.
Publicat: (2017-11-01)

Impact of Intravitreal Dexamethasone Implant on Vessel Diameters in Patients with Retinal Vein Occlusion
per: Busra Yilmaz Tugan, et al.
Publicat: (2019-01-01)

Analysis of Morphologic and Functional Outcomes in Macular Edema due to Central Retinal Vein Occlusion Treated with Intravitreal Dexamethasone Implant
per: Alfredo Niro, et al.
Publicat: (2018-01-01)

Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema
per: Taro Otawa, et al.
Publicat: (2022-06-01)

Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients
per: Hatice Ayhan Güler, et al.
Publicat: (2018-09-01)

Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa
per: Amelie Pielen, et al.
Publicat: (2017-01-01)

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
per: Carmen Antía Rodríguez-Fernández, et al.
Publicat: (2022-01-01)

Comment on “Intravitreal dexamethasone implants for diabetic macular edema”
per: Dan Călugăru, et al.
Publicat: (2018-12-01)

Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion
per: Marcel N. Menke, et al.
Publicat: (2016-01-01)

Intravitreal dexamethasone implant therapy for the treatment of cystoid macular Oedema due to hydroxychloroquine retinopathy: a case report and literature review
per: Seong Joon Ahn, et al.
Publicat: (2018-12-01)

Changes of central macular thickness post intravitreal ranibizumab and its associated factors among diabetic macular oedema patients
per: Tahir, Nursyafiqah Md
Publicat: (2020)

Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up
per: Cristina Nicula, et al.
Publicat: (2020-01-01)

The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario
per: Mert Simsek, et al.
Publicat: (2018-01-01)

Efficacy and Safety in Retinal Vein Occlusion Treated with at Least Three Consecutive Intravitreal Dexamethasone Implants
per: Julia Proença Pina, et al.
Publicat: (2016-01-01)

Effects of Intravitreal Ranibizumab Injection on Peripheral Retinal Microcirculation and Cytokines in Branch Retinal Vein Occlusion with Macular Edema
per: Kanako Yasuda, et al.
Publicat: (2023-05-01)

The Efficacy and Safety of Dexamethasone Intravitreal Implant for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis of Randomized Controlled Trials
per: Li Xiaodong, et al.
Publicat: (2022-01-01)

A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration.
per: Sivaprasad, S, et al.
Publicat: (2011)